Suppr超能文献

凝血酶原复合物浓缩剂:简要综述。

Prothrombin complex concentrates: a brief review.

作者信息

Samama C M

机构信息

Hotel-Dieu University Hospital, Department of Anaesthesiology and Intensive Care, Paris Cedex, France.

出版信息

Eur J Anaesthesiol. 2008 Oct;25(10):784-9. doi: 10.1017/S0265021508004675. Epub 2008 Jun 9.

Abstract

Prothrombin complex concentrates are haemostatic blood products containing four vitamin K-dependent clotting factors (II, VII, IX and X). They are a useful, reliable and fast alternative to fresh frozen plasma for the reversal of the effects of oral anticoagulant treatments (vitamin K antagonists). They are sometimes used for factor II or factor X replacement in patients with congenital or acquired deficiencies. They are widely prescribed in Europe. Several retrospective and prospective studies have demonstrated their efficacy in normalizing coagulation and in helping to control life-threatening bleeding. Few side-effects, mainly thromboembolic events, have been reported. The link between these events and prothrombin complex concentrate infusion has, however, often been brought into question. The use of prothrombin complex concentrates in new promising indications such as the management of massive bleeding requires prospective studies providing a high level of evidence in a high-risk setting.

摘要

凝血酶原复合物浓缩剂是含有四种维生素K依赖性凝血因子(II、VII、IX和X)的止血血液制品。它们是一种有用、可靠且快速的替代新鲜冰冻血浆的药物,可用于逆转口服抗凝治疗(维生素K拮抗剂)的效果。它们有时用于先天性或后天性缺乏症患者的因子II或因子X替代治疗。在欧洲,它们被广泛处方。多项回顾性和前瞻性研究已证明其在使凝血正常化以及帮助控制危及生命的出血方面的疗效。据报道,副作用很少,主要是血栓栓塞事件。然而,这些事件与凝血酶原复合物浓缩剂输注之间的联系常常受到质疑。在诸如大量出血管理等新的有前景的适应症中使用凝血酶原复合物浓缩剂需要前瞻性研究,在高风险环境中提供高水平的证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验